These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 12797930)

  • 21. Initial management of deep venous thrombosis in the outpatient setting.
    Groce JB
    Am J Health Syst Pharm; 2008 May; 65(9):866-74. PubMed ID: 18436734
    [No Abstract]   [Full Text] [Related]  

  • 22. Prevention of deep vein thrombosis in orthopedic surgery.
    Eichinger S; Kyrle PA
    Eur J Med Res; 2004 Mar; 9(3):112-8. PubMed ID: 15096320
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Letter 2: meta-analysis of trials comparing ximelagatran with low molecular weight heparin for prevention of venous thromboembolism after major orthopaedic surgery (Br J Surg 2005; 92: 1335-1344).
    Tangelder MJ; Bylock A; Held P
    Br J Surg; 2006 Mar; 93(3):374-5; author reply 375-6. PubMed ID: 16498578
    [No Abstract]   [Full Text] [Related]  

  • 24. Letter 3: meta-analysis of trials comparing ximelagatran with low molecular weight heparin for prevention of venous thromboembolism after major orthopaedic surgery (Br J Surg 2005; 92: 1335-1344).
    Agnelli G; Bergqvist D; Dahl O; Eriksson B; Rud Lassen M; Mouret P; Rosencher N
    Br J Surg; 2006 Mar; 93(3):375; author reply 375-6. PubMed ID: 16498579
    [No Abstract]   [Full Text] [Related]  

  • 25. [New antithrombotic agents. Towards a new therapeutic plan].
    Fiessinger JN
    Rev Prat; 2003 May; 53(10):1063-4. PubMed ID: 12846024
    [No Abstract]   [Full Text] [Related]  

  • 26. Forward thinking in orthopaedic surgery prophylaxis.
    Pownall M
    Hosp Med; 2005 Apr; 66(4):242-3. PubMed ID: 15889876
    [No Abstract]   [Full Text] [Related]  

  • 27. Fondaparinux as a novel therapeutic alternative in a patient with heparin allergy.
    Maetzke J; Hinrichs R; Staib G; Scharffetter-Kochanek K
    Allergy; 2004 Feb; 59(2):237-8. PubMed ID: 14763948
    [No Abstract]   [Full Text] [Related]  

  • 28. [New anticoagulants in the treatment of venous thrombo-embolic disease].
    Bura-Riviere A; Fiessinger JN
    Rev Med Interne; 2003 Nov; 24(11):738-44. PubMed ID: 14604751
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Prevention of venous thromboembolism after major orthopedic surgery: update and contribution of a specific synthetic inhibitor of factor Xa].
    Samama MM
    Rev Chir Orthop Reparatrice Appar Mot; 2003 Dec; 89(8):712-24. PubMed ID: 14726838
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fondaparinux: a new synthetic pentasaccharide for thrombosis prevention.
    Bounameaux H; Perneger T
    Lancet; 2002 May; 359(9319):1710-1. PubMed ID: 12049854
    [No Abstract]   [Full Text] [Related]  

  • 31. Extended anticoagulation therapy for the primary and secondary prevention of venous thromboembolism.
    Blanchard E; Ansell J
    Drugs; 2005; 65(3):303-11. PubMed ID: 15669876
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tolerance of Fondaparinux in Immediate-type Hypersensitivity to Heparins.
    Trog LM; Kahle B; Schindewolf M; Jappe U; Ludwig RJ
    Am J Med; 2015 Nov; 128(11):e21-2. PubMed ID: 26169891
    [No Abstract]   [Full Text] [Related]  

  • 33. Ximelagatran for prevention and treatment of venous thromboembolism.
    Kwok L; Boucher M
    Issues Emerg Health Technol; 2004 Jun; (57):1-4. PubMed ID: 15214359
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost consequence analysis of fondaparinux versus enoxaparin in the prevention of venous thromboembolism after major orthopaedic surgery in Belgium.
    Annemans L; Minjoulat-Rey MC; De Knock M; Vranckx K; Czarka M; Gabriel S; Haentjens P
    Acta Clin Belg; 2004; 59(6):346-57. PubMed ID: 15819379
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Fondaparinux as alternative anticoagulant to warfarin or low-molecular-weight heparin for recurrent venous thrombosis.
    Thachil J
    Ann Pharmacother; 2014 Mar; 48(3):420-4. PubMed ID: 24473488
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A new antithrombotic strategy, the selective inhibition of coagulation factors, and its importance to the orthopedic specialist.
    Bauer KA; Eriksson BI; Lassen MR; Turpie AG
    J South Orthop Assoc; 2002; 11(4):197-202. PubMed ID: 12597063
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Management of acute coronary syndromes with fondaparinux.
    Wienbergen H; Zeymer U
    Vasc Health Risk Manag; 2007; 3(3):321-9. PubMed ID: 17703640
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prophylaxis of venous thromboembolism in orthopaedic surgery.
    Abad JI
    Pathophysiol Haemost Thromb; 2002; 32(5-6):403-5. PubMed ID: 13679686
    [No Abstract]   [Full Text] [Related]  

  • 39. Fondaparinux is an effective alternative anticoagulant in pregnant women with high risk of venous thromboembolism and intolerance to low-molecular-weight heparins and heparinoids.
    Gerhardt A; Zotz RB; Stockschlaeder M; Scharf RE
    Thromb Haemost; 2007 Mar; 97(3):496-7. PubMed ID: 17334521
    [No Abstract]   [Full Text] [Related]  

  • 40. Fondaparinux: a new synthetic and selective inhibitor of Factor Xa.
    Bauer KA
    Best Pract Res Clin Haematol; 2004 Mar; 17(1):89-104. PubMed ID: 15171960
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.